Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
Source: Andrus Ciprian / Shutterstock.com
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is rising higher on Thursday after the clinical-stage biopharmaceutical company announced positive results from one of its brain cancer treatments.
According to a press release, early trials of MTX110 are showing promising results for patients suffering from brain cancer. Biodexa Pharmaceuticals says this includes extending the survival rates of those taking it.
Biodexa Pharmaceuticals notes that the median survival rate of individuals taking MTX110 in a Phase 1 trial was 26 months. To put that in perspective, the normal survival rate is only 10 months.
The company said the following about this news:
“Biodexa is hopeful MTX110 could potentially help extend patient life, offering much-needed hope to patients and their families. The company’s delivery method may also help prevent full-body exposure, which could minimize negative side effects. For cancers with such high mortality rates, any amount of extra time with a better quality of life is groundbreaking.”
BDRX Stock Movement Today
Today’s news has BDRX stock seeing heavy trading. That has more than 67 million shares changing hands as of this writing. This is well above its daily average trading volume of about 628,000 shares.
BDRX stock is up 106% as of Thursday morning.
Investors will find more of the most recent stock market stories ready to go below!
We have all of the hottest stock market news for Thursday! Among that is what’s happening with shares of Xilio Therapeutics (NASDAQ:XLO), Sega Sammy (OTCMKTS:SGAMY) and AMC Entertainment (NYSE:AMC) today. All of that news is available at the following links!
More Stock Market News for Thursday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.